KAPA Company Profile and Key Details

KAPA has shown mixed momentum, gaining 5.98% over the past week and -29.64% over the past quarter, though year-to-date performance is down -43.53%. Short-term trend indicators are bullishly aligned (SMA20 7.55%, SMA50 -7.01%, SMA200 -9.38%). The stock’s 14-day RSI is 52.69 (neutral), while the ATR of 0.07 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -73.59% below its high and over 114.6% above its low. Average 10-day trading volume of 167.81 thousand shares is below the 3-month average of 310.90 thousand, indicating normal recent market interest.

Kairos Pharma, Ltd. has 20.74 million shares outstanding. The public float is 11.81 million shares, elevated short interest at 8.61% of float. This equals 869.28 thousand shares. The short ratio is 0.07 days. Institutional investors hold 8.72% of the float. Insiders own 38.38%. Yu John S holds 5.34 million shares, Murali Ramachandran has 133.06 thousand shares and Samuelson Doug has 60.80 thousand shares.

Kairos Pharma, Ltd. generated EPS of -$0.30 over the past year. Five-year average earnings growth is -23.37%. Wall Street analysts project EPS growth of -25.6% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 14 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $12.00 to $4.00. The high target offers 1295.35% upside. The low target suggests 365.12% downside. The mean target is $8.86. This offers 930.23% upside. Kairos Pharma, Ltd. earnings surprise history is a mixed track record. The quarter that ended November 14, 2025, missed forecasts by -30.0%. The prior quarter beat by 33.33%. Over the last six quarters, Apple has recorded several small beats. These include 400.0% in November 14, 2024.

Kairos Pharma, Ltd. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.11. This means the shares are trading above this model’s fair value.

Our AI price prediction model suggests that Kairos Pharma, Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -2.14%, with price expected at $0.84 by January 02, 2026, within a range of $0.75 to $0.94 3-Month Outlook: Projected fall of -52.24%, reaching $0.41 by March 19, 2026, with a range of $0.35 to $0.47. 1-Year Outlook: Projected gain of 1869.94%, with price at $16.91 by December 18, 2026, within a range of $16.11 to $18.48.

Kairos Pharma, Ltd. (AMEX:KAPA) shares are down -43.53% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Kairos Pharma, Ltd. trading at a premium to the broader market with a P/E of -3.43. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $8.88, suggesting 934.48% upside. Our AI forecast model points to short-term weakness (-2.14% over two weeks), a medium-term fall (-52.24% over three months), and a longer-term gain (1869.94% over one year), with expected trading ranges indicating moderate volatility.

Kairos Pharma, Ltd. (AMEX:KAPA) closed at $0.83 USD, losing -$0.03 (-3.79%) from the previous close of $0.86. The stock is currently mid-range between its 52-week high and low $0.40 and $3.25. With a market capitalization of about $17.13 million, Kairos Pharma, Ltd. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.20). Key stats such as the average daily volume over the past year has been around 308.02 thousand shares, volume is running light vs its 52-week average. Headquartered in Los Angeles, CA, Kairos Pharma, Ltd. operates in the Healthcare sector and the Biotechnology industry. Led by CEO John S. Yu, the company employs approximately 1 people and listed since September 16, 2024. Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients.

Kairos Pharma, Ltd. trades at a P/E ratio of -3.43, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.26 suggesting the stock is closer to book value. The P/FCF stands at -4.28, also above market averages.